Inquiry Basket
Loading ......
Bone morphogenetic protein 1 occupies a curious niche in molecular biology: despite its name, it is not a bone morphogenetic protein at all. Unlike the dozen-plus members of the transforming growth factor beta superfamily that truly carry the BMP label, BMP1 is a zinc-dependent metalloproteinase belonging to the astacin family, more closely related to digestive enzymes than to growth factors. Its designation stems from its copurification with osteoinductive activity in bone extracts, but its real job is mechanical rather than hormonal — it clips the propeptides from procollagens and activates the enzymes that cross-link collagen fibers, thereby assembling the extracellular matrix that gives tissues their strength. Over the past decade BMP1 and its tolloid-like relatives have been recognized as master regulators that synchronize matrix assembly with the activation of growth factors, placing them at the heart of development, tissue repair, fibrosis, and inherited connective-tissue disease. This review examines how BMP1 builds and remodels the matrix, how its failure produces brittle bones and fragile eyes, and why it has re-emerged as a therapeutic target.
BMP1 is synthesized as a precursor whose mature form contains an astacin-like catalytic domain followed by a series of CUB and epidermal-growth-factor-like domains. The catalytic domain places it in the metzincin clan alongside matrix metalloproteinases and ADAM proteases, but BMP1 carries a distinctive disulfide-bonded loop near the active site that is unique to the tolloid-like subfamily and appears to gate substrate access. Humans express several related enzymes — mammalian tolloid, and mammalian tolloid-like 1 and 2 — together forming the BMP1/tolloid-like proteinase family. Genetic deletion of these enzymes is lethal in mice, underscoring their non-redundant roles in embryogenesis, yet in vitro the family members show overlapping activities, implying that spatial and temporal expression patterns, not catalytic specificity alone, dictate their physiological division of labor. A recurring theme is that the non-catalytic domains confer substrate preference: the isolated catalytic domain is relatively promiscuous, while the full-length protein targets procollagen and matrix-bound substrates with precision. This architecture lets BMP1 act as both a protease and a scaffold within the assembling matrix.
Figure 1. Schematic representation of BMP-1 domain structure with the positions of the six potential N-glycosylation sites. (Source: Garrigue-Antar L, et al. 2002)
The canonical function of BMP1 is to complete collagen maturation. Fibrillar procollagens are secreted as triple-helical precursors capped by N- and C-terminal propeptides that must be removed before the molecules can pack into fibrils. The C-terminal propeptides are cleaved by BMP1 and its tolloid-like relatives — the procollagen C-proteinases — while the N-terminal propeptides are removed by ADAMTS2, -3, and -14. Only after both cuts does the collagen trimer acquire the short telopeptides that allow proper alignment and fibril formation. This step is deceptively critical: defective C-propeptide cleavage leaves malformed collagen that cannot assemble correctly, weakening every tissue that depends on it, from bone to cornea. The procollagen C-proteinase enhancer proteins further modulate BMP1 activity at the substrate, illustrating how the enzyme is integrated into a multiprotein processing machine rather than acting alone. The result is a tightly controlled conversion of soluble precursor into the insoluble scaffold that bears mechanical load throughout the body.
BMP1's influence on matrix strength extends beyond propeptide removal to the activation of lysyl oxidase. Lysyl oxidase initiates the covalent cross-links that stabilize collagen and elastic fibers, and BMP1 proteolytically activates the lysyl oxidase precursor, coupling two essential maturation steps into one regulatory cascade. Intriguingly, lysyl oxidase is also cleaved by ADAMTS proteases at a site downstream of the BMP1 cut, and the region between these cuts contains tyrosine-sulfated residues that govern collagen binding — meaning the differential cleavage by BMP1 and ADAMTS enzymes fine-tunes where and how lysyl oxidase engages its substrate. This layered regulation reveals a principle of matrix biology: structural rigor depends not only on which enzymes act, but on the precise order and location of their cuts. When BMP1 activity is altered, both procollagen processing and cross-link initiation are perturbed, compounding the structural defect and explaining why BMP1 mutations produce such pleiotropic connective-tissue phenotypes.
A second, equally important role of BMP1 is the activation of signaling molecules embedded in the matrix. The enzyme processes latent transforming growth factor beta family members, certain growth differentiation factors, and insulin-like growth factors, converting quiescent precursors into active ligands and releasing anti-angiogenic fragments from parent proteins. In this capacity BMP1 couples matrix construction to growth-factor signaling, ensuring that tissue remodeling releases the cues that guide cell behavior. This dual life — building structure while awakening signals — explains why BMP1 sits at the center of morphogenesis and repair: a developing limb or a healing wound needs both a scaffold and the instructions to populate it, and BMP1 helps deliver both. It also means that dysregulated BMP1 can fuel pathological remodeling, since uncontrolled matrix turnover and growth-factor activation are hallmarks of fibrosis and tumor progression.
The clinical face of BMP1 deficiency is osteogenesis imperfecta, the heterogeneous group of brittle-bone disorders most often caused by mutations in the type I collagen genes. Recessive variants in BMP1 produce a distinctive form, sometimes designated type XIII, in which impaired C-propeptide cleavage of procollagen I disrupts collagen assembly. Strikingly, these patients often display normal or even paradoxically high bone mineral density despite recurrent fractures — a counterintuitive picture that complicates diagnosis and management, because the usual density–strength correlation fails. Cohort studies have linked BMP1 and COL1A1 C-propeptide cleavage variants to this high-bone-mass yet fragile phenotype, and individual cases carrying homozygous BMP1 missense changes show severe vertebral compression fractures with elevated density. The lesson is that bone quality, not merely quantity, depends on correct procollagen processing, and that BMP1 sits at the pivot where collagen maturation determines whether mineralized tissue is strong or merely dense.
Because type I collagen is abundant in the cornea and sclera, BMP1-related matrix defects manifest in the eye as well as the skeleton. Patients with osteogenesis imperfecta show altered corneal thickness, reduced corneal resistance, and a predisposition to glaucoma and other corneal pathology tied to abnormal collagen biomechanics. More directly, BMP1's role in fibrillar collagen maturation makes it central to corneal clarity and tensile integrity; faulty processing weakens the corneal stroma and shifts intraocular pressure dynamics. These ocular features reinforce that BMP1 is a systemic matrix enzyme whose failure is read in multiple tissues at once. The eye also offers a window into BMP1 in wound healing and scarring of transparent tissue, where precise collagen assembly is essential to preserve function, suggesting that modulating BMP1 could influence corneal repair without the fibrosis that clouds vision.
Beyond inherited disease, BMP1 has moved into the spotlight as a contributor to acquired fibrosis and remodeling. Circulating BMP1 levels are elevated in chronic kidney failure, hepatic fibrosis, and acute myocardial infarction in animal and human studies, and experimental inhibition of BMP1 — for example with a specific antibody against the BMP1.3 isoform — improved kidney, liver, and heart function in disease models. The mechanism links BMP1's growth-factor-activation role to pathological scar formation: by awakening latent TGF-beta and related signals, BMP1 helps convert injury into excess matrix deposition. This has prompted interest in BMP1 inhibitors for fibrotic and muscular diseases, including laminin-related congenital muscular dystrophy, where BMP1.3 expression is markedly enhanced in skeletal muscle. The therapeutic logic is appealing because it targets matrix turnover at a nodal point shared by several organs, but it must be balanced against the enzyme's essential roles in normal collagen maturation.
Targeting BMP1 is a double-edged proposition. On one side, dampening its activity could limit fibrosis, pathological remodeling, and, in specific genetic contexts, the progression of muscular dystrophy. On the other, BMP1 is required for ordinary collagen assembly, so broad inhibition risks weakening healthy tissue. The most promising strategies are isoform- or context-specific: antibodies directed at the BMP1.3 splice form, or agents that interfere with particular substrate interactions, may spare basal matrix maintenance while blunting disease-associated activity. Conversely, in osteogenesis imperfecta caused by BMP1 deficiency, the goal is the opposite — restoring or compensating for lost procollagen-processing capacity. The divergence of these aims highlights that BMP1 therapy must be bidirectional and precisely targeted, a challenge that structural knowledge of the active-site loop and non-catalytic domains is only beginning to address.
References
| Target | Cat. No. | Product Name | Size | Species | Application | Detection Sample | |
| BMP1 | DEIA-BJ1001 | Human BMP1(Bone morphogenetic protein 1) ELISA Kit | 96T | Human | Quantitative | Serum, plasma, tissue homogenates and other biological fluids. | Inquiry |
| Target | Cat. No. | Product Name | Host | Isotype | Application | |
| BMP1 | DCABH-4721 | Anti-BMP1 monoclonal antibody, clone 4F0 | Mouse | IgG1 | WB, ICC/IF | Inquiry |
| DCABH-10748 | Anti-BMP1 monoclonal antibody | Rabbit | IgG | WB, ELISA | Inquiry | |
| CABT-B423 | Anti-Bmpr1ba+b polyclonal antibody | Rabbit | IgG | IHC-Wmt | Inquiry | |
| DPABH-09447 | Anti-BMP1 (aa 972-986) polyclonal antibody | Rabbit | IgG | IHC-P, ELISA | Inquiry |
| Target | Cat. No. | Product Name | Expression System | Tag/Conjugate | Application | |
| BMP1 | DAG-P0231 | BMP1 peptide | N/A | Unconjugated | Blocking | Inquiry |
Loading ......
